Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Company Analysis

LGND Insider Trading

LIGAND PHARMACEUTICALS INC | Pharmaceutical Preparations

Comprehensive Trading Performance Summary

The investment history of corporate insiders at LIGAND PHARMACEUTICALS INC provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Pharmaceutical Preparations sector.

Transactions on Chart

Open Full Chart
Filing Date Trade Date Reporting Person Relationship Type Price Qty Total, $ Owned After Change, %
2013-12-14 02:46 2013-12-12 FOEHR MATTHEW W Officer - EVP and COO OPT+S $53.40 6,000 $320,400 44,929 0.0%
2013-12-10 02:53 2013-12-06 Sharp John P Officer - VP Finance and CFO SELL $56.08 6,000 $336,480 17,667 -25.4%
2013-11-29 19:38 2013-11-26 BVF PARTNERS L P/IL 10% owner SELL $57.27 527,505 $30,210,475 2,008,834 -20.8%
2013-11-21 02:49 2013-11-18 Sharp John P Officer - VP Finance and CFO OPT+S $53.00 1,123 $59,519 23,667 0.0%
2013-10-23 03:05 2013-10-18 HIGGINS JOHN L Director, Officer - President & CEO OPT+S $55.00 10,000 $550,000 106,581 0.0%
2013-09-26 01:54 2013-09-23 BVF PARTNERS L P/IL 10% owner SELL $44.50 359,023 $15,976,524 296,345 -54.8%
2013-09-13 22:07 2013-09-12 KNOTT DAVID M Director SELL $46.78 160,000 $7,484,080 51,396 -75.7%
2013-09-05 02:10 2013-08-30 Berkman Charles S Officer - VP, Gen. Counsel & Secretary OPT+S $47.54 28,323 $1,346,456 17,928 0.0%
2013-08-21 01:44 2013-08-16 Berkman Charles S Officer - VP, Gen. Counsel & Secretary OPT+S $42.63 14,583 $621,732 13,644 0.0%
2013-08-21 01:44 2013-08-16 Sharp John P Officer - VP Finance and CFO OPT+S $42.75 7,500 $320,619 24,166 0.0%
2013-08-21 01:44 2013-08-16 HIGGINS JOHN L Director, Officer - President & CEO OPT+S $42.85 10,000 $428,500 110,025 0.0%
2013-07-01 22:27 2013-06-28 DeSilva Nishan M Officer - VP, Corporate Development BUY $17.36 169 $2,934 15,659 +1.1%
2013-07-01 22:26 2013-06-28 Berkman Charles S Officer - VP, Gen. Counsel & Secretary BUY $17.36 815 $14,148 13,644 +6.4%
2013-07-01 22:27 2013-06-28 FOEHR MATTHEW W Officer - EVP and COO BUY $17.36 1,059 $18,384 44,929 +2.4%
2013-05-14 01:46 2013-05-10 Berkman Charles S Officer - VP, Gen. Counsel & Secretary SELL $26.66 4,000 $106,640 12,829 -23.8%
2013-01-26 01:17 2013-01-23 BVF PARTNERS L P/IL 10% owner BUY $19.78 39,600 $783,181 2,163,412 +1.9%
2012-12-19 00:36 2012-12-14 BVF PARTNERS L P/IL 10% owner BUY $18.63 5,386 $100,365 2,123,812 +0.3%
2012-12-11 00:40 2012-12-06 BVF PARTNERS L P/IL 10% owner BUY $17.94 50,100 $898,959 2,118,426 +2.4%
2012-12-06 00:53 2012-12-05 FOEHR MATTHEW W Officer - EVP and COO BUY $17.99 370 $6,656 37,870 +1.0%
2012-12-06 00:53 2012-12-05 HIGGINS JOHN L Director, Officer - President & CEO BUY $18.03 2,000 $36,060 112,025 +1.8%
2012-12-03 22:13 2012-11-29 KNOTT DAVID M Director SELL $19.90 20,000 $398,070 211,396 -8.6%
2012-11-29 23:04 2012-11-27 KNOTT DAVID M Director SELL $19.54 100,000 $1,953,600 231,396 -30.2%
2012-11-16 02:11 2012-08-29 KNOTT DAVID M Director BUY $16.36 2,743 $44,875 2,743 +100.0%
2012-11-03 01:36 2012-10-26 BVF PARTNERS L P/IL 10% owner BUY $15.19 16,591 $252,022 741,627 +2.3%
2012-09-10 20:55 2012-09-07 Berkman Charles S Officer - VP, Gen. Counsel & Secretary SELL $18.77 4,249 $79,754 14,329 -22.9%
2012-08-15 02:19 2012-08-13 HIGGINS JOHN L Director, Officer - President & CEO BUY $16.39 500 $8,195 110,025 +0.5%
2012-06-05 19:56 2012-06-01 Aryeh Jason Director BUY $11.98 700 $8,386 285,036 +0.2%
2012-05-25 20:50 2012-05-24 KNOTT DAVID M Director SELL $11.62 196,000 $2,277,520 41,583 -82.5%
2012-05-25 20:50 2012-05-24 KNOTT DAVID M Director BUY $11.62 196,000 $2,277,520 264,661 +285.5%
2012-05-24 21:01 2012-05-23 Patel Sunil Director BUY $11.38 1,500 $17,070 29,705 +5.3%
2012-05-08 20:54 2012-05-04 HIGGINS JOHN L Director, Officer - President & CEO BUY $12.04 1,000 $12,040 108,275 +0.9%
2012-03-09 02:24 2012-03-08 Berkman Charles S Officer - VP, Gen. Counsel & Secretary SELL $15.76 3,606 $56,832 17,328 -17.2%
2011-11-23 00:29 2011-11-18 BVF PARTNERS L P/IL 10% owner BUY $10.65 511,040 $5,442,167 2,068,326 +32.8%
2011-11-15 02:29 2011-11-10 KNOTT DAVID M Director BUY $11.58 4,000 $46,320 54,704 +7.9%
2011-11-15 02:31 2011-11-10 Sabba Stephen L Director BUY $11.60 2,000 $23,190 12,704 +18.7%
2011-10-28 23:55 2011-10-26 BVF PARTNERS L P/IL 10% owner BUY $13.91 6,020 $83,751 1,741,800 +0.3%
2011-10-25 23:22 2011-10-21 BVF PARTNERS L P/IL 10% owner BUY $13.93 4,600 $64,062 1,738,000 +0.3%
2011-10-21 00:40 2011-10-18 BVF PARTNERS L P/IL 10% owner BUY $13.90 14,100 $196,024 1,735,000 +0.8%
2011-10-14 23:16 2011-10-12 BVF PARTNERS L P/IL 10% owner BUY $13.65 75,353 $1,028,568 1,726,000 +4.6%
2011-10-07 00:02 2011-10-04 BVF PARTNERS L P/IL 10% owner BUY $12.78 14,400 $183,961 362,080 +4.1%
2011-09-06 23:59 2011-09-01 KNOTT DAVID M Director BUY $15.21 10,000 $152,100 407,563 +2.5%
2011-09-01 20:26 2011-08-30 KNOTT DAVID M Director BUY $14.86 11,940 $177,400 405,083 +3.0%
2011-08-31 00:00 2011-08-26 KNOTT DAVID M Director BUY $13.08 61,559 $805,352 402,843 +18.0%
2011-08-27 00:48 2011-08-25 KNOTT DAVID M Director BUY $12.57 55,000 $691,350 62,783 +706.7%
2011-08-25 23:41 2011-08-23 KNOTT DAVID M Director BUY $12.58 41,490 $521,894 28,300 +100.0%
2011-08-24 13:16 2011-08-19 KNOTT DAVID M Director BUY $11.96 31,269 $374,115 367,084 +9.3%
2011-08-23 01:05 2011-08-18 BVF PARTNERS L P/IL 10% owner BUY $11.92 37,871 $451,388 1,671,562 +2.3%
2011-08-19 22:49 2011-08-17 KNOTT DAVID M Officer - Director BUY $12.06 24,133 $291,003 358,615 +7.2%
2011-08-16 01:00 2011-08-12 KNOTT DAVID M Director BUY $11.99 18,348 $219,901 352,382 +5.5%
2011-08-16 01:24 2011-08-11 BVF PARTNERS L P/IL 10% owner BUY $11.19 1,394 $15,601 1,636,862 +0.1%
SHOW ENTRIES

How to Interpret $LGND Trades

Not every insider transaction in LIGAND PHARMACEUTICALS INC is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $LGND shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.

Data Source & Accuracy for LGND

Insider activity data for LIGAND PHARMACEUTICALS INC is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $LGND, allowing you to follow the capital of those with the most intimate knowledge of the company.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.